Röjdmark S, Andersson D E, Hed R, Sundblad L
Horm Metab Res. 1980 Jul;12(7):285-90. doi: 10.1055/s-2007-996272.
The present investigation was carried out in 16 healthy subjects in order to study whether calcium antagonism would affect the hypoglycemic response to insulin, and/or whether it would affect the insulin and glucose responses to glucagon. For this purpose verapamil, a potent calcium-blocking agent, was used. Verapamil infused alone did not affect the basal insulin or glucose concentrations. However, such infusion reduced the hypoglycemic response to insulin. Furthermore, the glucose response to glucagon was augmented by simultaneous infusion of verapamil, whereas the insulin response to glucagon was unaffected. When healthy volunteers were simultaneously infused with both calcium and verapamil the glucose response to glucagon was no longer augmented. The insulin response to glucagon also remained unaffected. These findings indicate that intravenous verapamil has hyperglycemic effects, unrelated to insulin, under certain conditions. They also imply that exogenous hypercalcemia counteracts the augmentative effect of verapamil on the glucose response to glucagon.
本研究对16名健康受试者进行，旨在探讨钙拮抗作用是否会影响对胰岛素的低血糖反应，和/或是否会影响对胰高血糖素的胰岛素和葡萄糖反应。为此，使用了一种强效钙阻滞剂维拉帕米。单独输注维拉帕米不影响基础胰岛素或葡萄糖浓度。然而，这种输注降低了对胰岛素的低血糖反应。此外，同时输注维拉帕米可增强对胰高血糖素的葡萄糖反应，而对胰高血糖素的胰岛素反应未受影响。当健康志愿者同时输注钙和维拉帕米时，对胰高血糖素的葡萄糖反应不再增强。对胰高血糖素的胰岛素反应也仍未受影响。这些发现表明，在某些情况下，静脉注射维拉帕米具有与胰岛素无关的高血糖作用。它们还意味着外源性高钙血症可抵消维拉帕米对胰高血糖素葡萄糖反应的增强作用。
